Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Hydromethylthionine mesylate (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Nov 2016 Results of a pre-specified analysis published in The Lancet.
    • 27 Jul 2016 According to an Alzheimer's Association media release, the results from this study were presented at the 2016 Alzheimer's Association International Conference (AAIC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top